Okay, let's talk about how the company is supposedly failing to deliver.
When the 13D guy was running the show, he prevented the clinical trial from going forward for 7 months. By my math, that means that if the clinical trial had started when it COULD have started, the company would be 7 months closer to applying to the FDA.
But since he left, the do-nothing lazy slobs at CYDY have just managed to do several clinical trials for Leronlimab against COVID-19, for Leronlimab as a treatment for long-hauler syndrome, and for Leronlimab against cancer.
And they've hired several people to get the paperwork finally filed for the HIV application.
Boy, they sure are lazy, and they sure haven't made a bit of progress. It's absolutely their fault that bureaucracies in other countries are throwing stumbling blocks in their path (not to mention the actions of the U.S. FDA).
By all means, let's blame the company for the very obvious downward pressure being exerted on the stock when you watch Level 2, and let's blame the company for nasty tweets from a shortseller, and let's not forget the constant barrage of unfounded childishly written accusations by the people who want to spend 350 million bucks of shareholder money for a testing company that at least 2 of them would profit from.
No. Let's blame CYDY. It must be management's fault, for wasting all that time getting clinical trials going.
When the 13D guy was running the show, he prevented the clinical trial from going forward for 7 months. By my math, that means that if the clinical trial had started when it COULD have started, the company would be 7 months closer to applying to the FDA.
But since he left, the do-nothing lazy slobs at CYDY have just managed to do several clinical trials for Leronlimab against COVID-19, for Leronlimab as a treatment for long-hauler syndrome, and for Leronlimab against cancer.
And they've hired several people to get the paperwork finally filed for the HIV application.
Boy, they sure are lazy, and they sure haven't made a bit of progress. It's absolutely their fault that bureaucracies in other countries are throwing stumbling blocks in their path (not to mention the actions of the U.S. FDA).
By all means, let's blame the company for the very obvious downward pressure being exerted on the stock when you watch Level 2, and let's blame the company for nasty tweets from a shortseller, and let's not forget the constant barrage of unfounded childishly written accusations by the people who want to spend 350 million bucks of shareholder money for a testing company that at least 2 of them would profit from.
No. Let's blame CYDY. It must be management's fault, for wasting all that time getting clinical trials going.
16
